Loading…
ASND
Ascendis Pharma A/S
NASDAQ· Healthcare· Biotechnology· CUSIP K08588103
$242.99+1.71%Price as of Oct 23, 00:46 UTC · updated once a day, after the close
At a glance
Ascendis Pharma A/S (ASND) is listed on NASDAQ and classified in Biotechnology, part of the Healthcare sector. It is headquartered in Hellerup, Denmark and has 1,189 employees. The company is worth $15.99B and trades at 18.6x its earnings of the last twelve months; the median for its sector is 24.3x. Revenue was €720.13M in fiscal 2025, up 98.0% from the year before. It reported a net loss of €228.03M. The share price is 13.9% below its 52-week high of $282.15. 4 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Israel Englander (Millennium Management), at $142.27M. In that quarter, 4 of them opened or added to the position. No open-market insider trades in it were filed over the last 30 days.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Key metrics
- Market cap
- $15.99B
- P/E
- 18.6x
- Forward P/E
- 22.5x
- P/B
- 9.9x
- Dividend yield
- 0.00%
- Payout
- —
- EPS
- $13.05
- ROE
- 118.78%
- Profit margin
- 70.84%
- Revenue growth
- +114.70%
- Beta
- —
- 52-week high
- $282.15
- 52-week low
- $188.07
History
Year by year, from the annual reports; dividends from the payments themselves.
Revenue, debt and profit are in EUR, the currency the company reports in — not converted to dollars. Dividends are in dollars.
Bars are year-end balances; lines are what happened during the year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▲ +64.4% over 5Y.
today you would have $1,485.72▲ +48.6%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 4 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $213.24 | $137.67 | $125.95 | $122.13 | |
| EPS | -€3.76 | -€6.53 | -€8.55 | -€10.40 | |
| Profit margin | -142.24% | -31.67% | -103.97% | -180.51% | -1139.63% |
| ROE | — | — | — | — | -221.45% |
This company reports in EUR, and the stock trades in dollars. P/E, P/S, P/B and payout would divide dollars by EUR, so they are not shown; EPS is in EUR. Margin, ROE and dividend yield do not depend on the currency.
Median of the years shown; P/E years above 200x are left out.
Fair price, seven ways
Seven formulas applied to the reported numbers, each with its assumption next to the result. None of them predicts a price.
Earnings
$84.91
Square root of 22.5 × earnings × book value. Blind to intangibles, so it undervalues software and brands.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Earnings
$316.92
Median P/E of 24.3 among peers in the sector.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Cash flow
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Operating
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Dividends
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| EXELExelixis Inc | $65.31 | 20.4x | 8.8x | 0.00% | 44.39% | $16.18B |
| CRLCharles River Laboratories International Inc | $339.66 | — | 5.7x | 0.00% | -7.52% | $16.36B |
| SOLVSolventum Corp | $87.45 | 10.6x | 3.1x | 0.00% | 33.96% | $14.89B |
| NBIXNeurocrine Biosciences Inc |
About the company
- 1,189
- Hellerup, Denmark